IMM 11.0% 40.5¢ immutep limited

Edison Healthcare Insight report - August 2015. Prima Biomed is...

  1. 212 Posts.
    Edison Healthcare Insight report - August 2015. Prima Biomed is mentioned on page 42 of 58...

    http://www.google.com.au/url?sa=t&rct=j&q=&esrc=s&source=web&cd=9&ved=0CE0QFjAIahUKEwiPkrahr7nHAhUkIaYKHQ2IBo8&url=http://www.edisoninvestmentresearch.com/?ACT=19&ID=14694&dir=monthlybooks&field=19&ei=MK3WVY-6L6TCmAWNkJr4CA&usg=AFQjCNGY7Ak6ocHa4byCxfoWeWUy25uKcA&sig2=ABboT3KbJ1S1lAlITj3Gbg

    Immunotherapies are among the most promising class of products for cancer and
    autoimmune diseases. The LAG-3 products are potentially first-in-class, each with distinct
    mechanisms and applications. CVac is a similar treatment to Dendreon's Provenge, with an​
    enhanced and more efficient production platform.
    Last edited by gowie77: 21/08/15
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
40.5¢
Change
0.040(11.0%)
Mkt cap ! $588.3M
Open High Low Value Volume
37.0¢ 40.5¢ 36.8¢ $1.822M 4.681M

Buyers (Bids)

No. Vol. Price($)
1 19739 39.0¢
 

Sellers (Offers)

Price($) Vol. No.
40.5¢ 45420 1
View Market Depth
Last trade - 16.10pm 30/08/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.